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Introduction {#sec1}
============

Cancer is difficult to treat when cells from the primary tumor spread to other sites of the body to form distant metastases. The metastatic cascade is a multi-step process including detachment from neighboring cells, movement to and entry into the circulation, exit from the circulation, and colonization of a secondary site ([@bib10]). It has long been speculated that metastatic cells acquire disseminating and stem cell properties by hijacking a developmental program called epithelial-to-mesenchymal transition (EMT) ([@bib6], [@bib13], [@bib14], [@bib18], [@bib19]). Cells that undergo EMT often decrease expression of epithelial proteins such as adherent junction molecule E-cadherin (E-cad) and frequently gain expression of mesenchymal proteins such as fibroblast-specific protein 1 (Fsp1) ([@bib14], [@bib17]). The potential crucial role of EMT in acquiring invasive and metastatic properties, and even the very existence of EMT in unperturbed tumors, is heavily debated ([@bib4], [@bib5], [@bib7], [@bib11], [@bib20], [@bib21]). We previously demonstrated that EMT exists in unperturbed tumors *in vivo*, by generating a mouse model for ductal mammary carcinomas (on the basis of the expression of polyoma middle-T antigen \[PyMT\]) in which endogenous E-cad is fused to monomeric CFP (mCFP). Using flow cytometry, we identified a small population of cancer cells in which E-cad is downregulated and all classical mesenchymal markers are upregulated, a population we refer to as E-cad^LO^ cells. Using flow cytometry, intravital microscopy, and transplantation assays, we identified that E-cad^LO^ cells can disseminate and upon arrival at a distant site revert to an epithelial state to seed metastases, thereby providing direct evidence for the existence of EMT in unperturbed tumors ([@bib3]). However, the commonly assumed crucial role of EMT in metastasis has recently been challenged in a study in the same PyMT-breast cancer model. In this study, an elegant EMT lineage-tracing reporter was developed that permanently marks cells fluorescently upon expression of the mesenchymal protein Fsp1. Strikingly, the authors found that the vast majority of metastases were negative for this genetic inheritable mark ([@bib8]). Therefore, it was concluded that these metastases are seeded by disseminating cells that are in an epithelial state rather than a mesenchymal state, which strongly challenges the idea that EMT is crucial for metastasis. However, this interpretation and conclusion hold true only if all cells that become mesenchymal are marked by *fsp1*-mediated lineage tracing. This has been challenged in many reports and reviews ([@bib1], [@bib2], [@bib4], [@bib5], [@bib7], [@bib11], [@bib16], [@bib20], [@bib21]). For example, [@bib20] showed using immunofluorescence staining of PyMT tumor sections that only a small fraction of mesenchymal cancer cells positive for Zeb1 or Snail also express Fsp1. To further investigate this, we here combine the *fsp1*-based lineage-tracing reporter with our real-time E-cad-based epithelial-mesenchymal state reporter and further characterize the disseminating cells of metastatic PyMT-mediated mammary tumors.

Results and Discussion {#sec2}
======================

To further characterize the EMT status of disseminating cells, we crossed the EMT lineage-tracing mouse model used by [@bib8] (*MMTV*-PyMT; *fsp1*-Cre; *R26*-mTmG) with our real-time E-cad-based EMT reporter (E-cad-mCFP) ([Figure 1](#fig1){ref-type="fig"}A). The resulting mice (*MMTV*-PyMT; *fsp1*-Cre; *R26*-mTmG; E-cad-mCFP) spontaneously develop mammary tumors that resemble invasive ductal carcinoma ([@bib12]). All cancer cells in these tumors ubiquitously express membrane-targeted Tomato (from here on referred to RFP^+^), which is lost upon Cre-mediated recombination, concomitantly leading to gain of membrane-targeted GFP (GFP^+^) ([Figure 1](#fig1){ref-type="fig"}A). Expression of the Cre recombinase is driven by the promoter of the mesenchymal protein *fsp1* to genetically and inheritably mark cells that have been in a mesenchymal state ([@bib8], [@bib23]). Last, in all epithelial cells (including cancer cells), the endogenous E-cad is tagged with a mCFP, which is delocalized from the membrane or lost upon EMT ([@bib3]; [Figure 1](#fig1){ref-type="fig"}A).Figure 1Epithelial-to-Mesenchymal Transition Reported by Historical Lineage-Tracing Reporter and Current E-Cadherin Status in Murine Metastatic Mammary Carcinoma Model(A) Schematic of fluorescent transgenic mouse model, carrying polyoma middle-T (PyMT) oncogene driven by the mammary gland specific *MMTV* promoter, Cre recombinase under the control of the *fsp1* promoter, endogenous E-cad labeled with mCFP, and ubiquitous expression from the *R26* locus of membranous RFP-STOP, which is flanked by *lox*P sites, leading to excision and subsequent expression of membranous GFP upon Cre expression.(B) Top panel: representative multi-photon images of the fluorescent PyMT mammary tumors from recipient mice. Scale bar, 100 μm. Bottom panel: high-magnification images of the E-cad-mCFP and RFP channel of the boxed area in the top left image. Scale bar, 50 μm.(C) Representative scatterplot from flow cytometry analysis of primary tumor of recipient mice for either absence of endogenous E-cad-mCFP expression and antibody staining (E-cad^LO^) or presence of high expression of E-cad and staining for Ab (E-cad^HI^ tumor cells) or subdivision of RFP^+^ or GFP^+^ cells.(D) Relative mRNA expression of classical EMT marker genes (E-cad, Vimentin \[Vim\], fibronectin \[FN\], Zeb1, N-cad \[N-cadherin\], Slug) determined using qPCR of sorted RFP^+^E-cad^Hi^, RFP^+^E-cad^LO^, RFP^+^GFP^+^, and GFP^+^ cells from primary tumors. Plotted mean and SD of n = 3 mice.(E) Quantification of lung metastases of all transplanted mice.(F) Representative multi-photon image of metastases in lung secetion from recipient mice. Outlining of lung tissue is shown by white dashed line. Scale bar 500 μm.

In order to determine whether previous reported results can be recapitulated in this new mouse model, we established primary organoid cultures from highly aggressive tumors and isolated the epithelial population of cancer cells (i.e., E-cad-mCFP^+^; RFP^+^; GFP^−^ cells). As we have previously demonstrated ([@bib3]), orthotopic transplantation of these epithelial cancer cells in recipient mice results in primary tumors that are morphologically indistinguishable from the original tumor and metastasize to the lungs spontaneously ([Figure 1](#fig1){ref-type="fig"}B; [Table S1](#mmc1){ref-type="supplementary-material"} for all details on the mice included in this study). Importantly, because the healthy cells of these recipient mice are not fluorescent, epithelial and mesenchymal cancer cells can be distinguished on the basis of the expression of E-cad-mCFP, GFP, and RFP. We observed that the majority of cancer cells in primary tumors were in an epithelial state (i.e., E-cad-mCFP^+^ cells, from here on referred to as E-cad^HI^ cells) and expressed classical epithelial markers. In addition to E-cad^HI^ cells, we found a much smaller population of E-cad^LO^ cells (on average \<5%) ([Figure 1](#fig1){ref-type="fig"}C). This percentage was higher than we have reported before, most likely because of a change of our mouse facility, different flow cytometry filters, and potentially the aggressive nature of the donor tumors. Indeed, we observed a relationship between the number of E-cad^LO^ cells in the tumor, which is related to the amount of lung metastases ([Figure S1](#mmc1){ref-type="supplementary-material"}). Importantly, and in line with our previous findings, E-cad^LO^ cells were truly mesenchymal cells, as they expressed all classical mesenchymal markers ([Figure 1](#fig1){ref-type="fig"}D). Last, in line with previous findings ([@bib8], [@bib23]), we observed that the vast majority of lung metastases were in an epithelial state (i.e., E-cad-mCFP^+^) and were not marked by the *fsp1*-mediated EMT lineage-tracing reporter (i.e., RFP^+^ instead of GFP^+^) ([Figures 1](#fig1){ref-type="fig"}E and 1F), indicating that these cells never expressed *fsp1*.

Although the lack of GFP^+^ metastases was previously interpreted as evidence for the lack of requirement of EMT for seeding metastases, this interpretation holds true only if all cells undergoing EMT are genetically and inheritably marked. To test this, we isolated tumor cells from primary tumors on the basis of the presence of GFP, RFP, and membranous E-cad using flow cytometry ([Figure 1](#fig1){ref-type="fig"}C). In line with microscopy analyses ([Figure 1](#fig1){ref-type="fig"}B) and previous data ([@bib3]), the majority of cancer cells were E-cad^HI^ and RFP^+^, and only a small number of cells were positive for GFP ([Figure 1](#fig1){ref-type="fig"}C). Similar to E-cad^LO^ cells, the GFP^+^RFP^+^ and GFP^+^ cells also expressed mesenchymal markers ([Figure 1](#fig1){ref-type="fig"}D). Although there was a large variation among individual mice, the percentage of GFP^+^ cells was on average 0.3%, while that of mesenchymal E-cad^LO^ cells was on average 5% ([Figures 2](#fig2){ref-type="fig"}A--2C). From these data, we conclude that the *fsp1*-based lineage-tracing reporter marks only a minor fraction of all mesenchymal cells in the primary tumor. To test whether this holds true not only for primary tumor cells but also for disseminating cells, we isolated circulating tumor cells (CTCs) from the right heart chamber and analyzed them using our flow cytometer strategy. Despite a large variation regarding the number of CTCs in each individual, 25% of all disseminating cells were in a mesenchymal state (E-cad^LO^), while only 0.01% were GFP^+^ ([Figures 2](#fig2){ref-type="fig"}D--2F). Importantly, when we injected mesenchymal E-cad^LO^ cells into the circulation, these cells formed E-cad^+^ metastases, illustrating that these cells were plastic and could seed epithelial metastases ([Figures 2](#fig2){ref-type="fig"}G and 2H). Combined, our data show that the vast majority of disseminating cells in a mesenchymal state that have metastatic potential are not marked by the *fsp1*-based EMT lineage-tracing reporter.Figure 2Mesenchymal E-cad^LO^ Population Exceeds *fsp1*-Lineage-Traced Population in Primary Tumor and Circulation and Has Metastatic Potential(A) Percentage of GFP^+^ (green), GFP^+^ RFP^+^ (yellow), and RFP^+^ (red) tumor cells in primary tumors of recipient mice. n = 16 mice.(B) Percentage of E-cad^HI^ (blue), E-cad^LO^ (light blue) tumor cells in primary tumors of recipient mice. n = 16 mice.(C) Comparison of percentage of E-cad^LO^ (light blue) with GFP^+^ (green) and GFP^+^ RFP^+^ (yellow) tumor cells in primary tumors of recipient mice. n = 16 mice.(D) Percentage of GFP^+^ (green), GFP^+^ RFP^+^ (yellow), and RFP^+^ (red) circulating tumor cells collected from the right cardiac chamber of recipient mice. n = 16 mice.(E) Percentage of E-cad^HI^ (blue), E-cad^LO^ (light blue) circulating tumor cells collected from the right cardiac chamber of recipient mice. n = 16 mice.(F) Comparison of percentage of E-cad^LO^ (light blue) with GFP^+^ (green) and GFP^+^ RFP^+^ (yellow) circulating tumor cells collected from the right cardiac chamber of recipient mice. n = 16 mice.(G) Top panel: schematic overview of experimental setup: fluorescence-activated cell sorting (FACS)-sorted E-cad^HI^ or E-cad^LO^ cells of orthotopically transplanted mice were injected in the tail vein of acceptor mice. Bottom panel: quantification of lung metastases of all transplanted mice. n = 3 mice per condition.(H) Representative multi-photon image of lung metastasis from (G). Scale bar, 500 μm. Right panels: zoom of boxed area showing detected E-cad-mCFP and RFP signal. Scale bar, 100 μm.

Final Remarks {#sec2.1}
-------------

It has been extensively hypothesized that EMT is crucial for metastasis ([@bib10], [@bib14], [@bib17]). This idea was challenged by observations that metastases can be seeded by cells that have not expressed *fsp1*-driven Cre recombinase at any point during the metastatic cascade ([@bib8], [@bib9], [@bib23]). This observation only disputes a crucial role of EMT for metastasis, if all cells undergoing EMT are labeled by the *fsp1*-mediated lineage-tracing mark. In line with previous studies ([@bib1], [@bib2], [@bib4], [@bib5], [@bib7], [@bib11], [@bib16], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22]), we show that this is not the case. Instead, we find that the vast majority of mesenchymal cells in primary tumors and during dissemination are not marked by this historical *fsp1* marker. Therefore, the lack of metastases that are seeded by cells that express *fsp1* does not necessarily mean that EMT is not required during the metastatic cascade. A potential explanation is the occurrence of partial EMT, resulting in the presence of hybrid cells that display some characteristics of both epithelial and mesenchymal states. Indeed, different transition states (i.e., partial EMT) have recently been identified ([@bib2], [@bib15]). In line with this idea, recent studies in pancreatic cancer have shown that partial EMT is important for metastasis formation in specific organs ([@bib16]). Our data are fully consistent with previous findings that EMT represents a spectrum of different cellular states, rather than a binary phenomenon, each of which may have different roles during the metastatic cascade. So, despite a lack of direct evidence for a crucial role of EMT in metastasis, our data illustrate that the suggestion that EMT is required for metastasis is less controversial than recently assumed and stated.

STAR★Methods {#sec3}
============

Key Resources Table {#sec3.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**CD41 clone eBioMWReg30eBioscienceCat\#13-0411-82RRID:[AB_763484](nif-antibody:AB_763484){#intref0010}CD45 clone 30-F11eBioscienceCat\#13-0451-85RRID:[AB_466447](nif-antibody:AB_466447){#intref0015}streptavidin-conjugated PerCPBiolegendCat\#405213E-cad-eFluor660eBioscienceCat\#50-3249-82RRID:[AB_11040003](nif-antibody:AB_11040003){#intref0020}**Chemicals, Peptides, and Recombinant Proteins**DNase IRocheCat\#4716728001IsofluranePharmachemie BV, Haarlem, NetherlandsCat\# 45.112.110Histopaque-1077SigmaCat\#10771DMEM/F12 + GlutaMAXInvitrogen Life TechnologiesCat\#10565018TH LiberaseRocheCat\#5401151001TrizolInvitrogen Life TechnologiesCat\#15596018ChloroformSigmaCat\#77617-500mlSucroseSigmaCat\#S0389-500GL-LysineSigmaCat\#W384720-100G-KSodium Dihydrogen Phosphate DihydrateFischer ScientificCat\#RS228270015ParaformaldehydeAlfa AesarCat\#43368Sodium metaperiodateMerckCat\#106597TrypsinSigmaCat\# T1426Collagenase ARocheCat\# 10103578001BMEPathClearCat\# 3533-005-02B27Thermo Fisher ScientificCat\# 17504044**Critical Commercial Assays**High-Capacity cDNA Reverse Transcription KitApplied BiosystemsCat\#4368814Power SYBR Green PCR Master MixApplied BiosystemsCat\#A25742**Experimental Models: Cell Lines**1805473 organoid line *MMTV*-PyMT; *fsp1*-Cre; *R26*-mTmG; E-cad-mCFPThis manuscriptN/A1814468 organoid line *MMTV*-PyMT; *fsp1*-Cre; *R26*-mTmG; E-cad-mCFPThis manuscriptN/A1926833 organoid line MMTV-PyMT; *fsp1*-Cre; *R26*-mTmG; E-cad-mCFPThis manuscriptN/A**Experimental Models: Organisms/Strains**NOD-scid Il2ry^null^B2m^null^Jackson LaboratoryStock No:010636*MMTV*-PyMTJackson LaboratoryStock No:002374*fsp1*-CreJackson LaboratoryStock No:012641*R26*-mTmG in house backcrossed to FVB/NJackson LaboratoryStock No:007676E-cad-mCFPGift from Hans CleversN/A**Oligonucleotides**qPCR primers[@bib3]see [Table S2](#mmc1){ref-type="supplementary-material"}**Software and Algorithms**Prism v7Graphpad<https://www.graphpad.com/scientific-software/prism/>Excel 2010Microsoft Office<https://products.office.com/en/excel>FlowJo v10TreeStar<https://www.flowjo.com/solutions/flowjo/downloads>LasXLeica Microsystems<https://www.leica-microsystems.com/products/microscope-software/p/leica-las-x-ls/>

Lead Contact and Materials Availability {#sec3.2}
---------------------------------------

All mouse organoid generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jacco van Rheenen (<j.v.rheenen@nki.nl>).

Experimental Model and Subject Details {#sec3.3}
--------------------------------------

*R26*-mTmG C57BL/6J were purchased from Jackson Laboratory and were backcrossed in house to FVB. Further, *MMTV*-PyMT (FVB) mice and *fsp1*-Cre (Balb-c) were purchased from Jackson Laboratory and E-cad-mCFP mice were a gift from Hans Clevers. Mice were crossed *MMTV*-PyMT; *fsp1*-Cre; *R26*-mTmG; E-cad-mCFP transgenic mice.

As acceptors for orthotopic transplantation and tail vein injection 8 to 16 weeks old female NOD-scid Il2ry^null^B2m^null^ mice (referred in the text to as NSG-β2 m^−/−^ mice) were used. All animal experiments were approved by the Animal Welfare Committee of the NKI, in accordance with national guidelines. All animals were maintained in the animal department of the NKI, housed in individually ventilated cage (IVC) systems under specific pathogen-free conditions and received food and water *ad libitum*.

Method Details {#sec3.4}
--------------

### Isolation and culturing of donor mouse organoids {#sec3.4.1}

*MMTV-PyMT; fsp1*-Cre; R26-mTmG; E-cad-mCFP transgenic mice spontaneously developed mammary tumors at the age of 8-14 wks. Upon tumor formation, mice were sacrificed and mammary tumor organoids were isolated from three independent donors. Mammary tumors were minced and enzymatically digested gently shaken for 30 min at 37 C in digestion mix (0.2% trypsin (from bovine pancreas, Sigma) and 0.2% collagenase A (Roche)). The digested tumors were spun down and cell fragments were ebedded in BME (RGF BME type 2 pathClear). Mammary tumor organoid medium contained DMEM/F12 Glutamax (GIBCO), 2% B27 (Invitrogen), 10 ng/ml FGF. In order to ensure to start from a pure epithelial population, RFP^+^, E-cad-mCFP^HI^ cells were selected by FACS sorting and expanded by culturing as tumor organoid lines.

### FACS sorting of primary mouse material {#sec3.4.2}

Deoxygenated blood was withdrawn from the right cardiac ventricle while the mice were under anesthesia (1.5% isoflurane). Red blood cells were depleted by NH4Cl treatment. The remaining circulating tumor cells and immune cells were collected (spun down, 4 minutes 500 RCF at RT).

Orthotopic mammary tumors were collected and minced on ice using sterile scalpels, followed by digestion in PBS supplemented with 25 μg/ml DNase I (Roche) and 5 Wünsch units TH Liberase /ml (Roche) at 37 C for 35 min. Digested cell clumps were filtered through a 70 μm filter (BD Falcon) while adding DMEM/F12 + GlutaMAX and spun down for 4 min at 500 RCF at 4 C. Pellets were resuspended in 5mM EDTA/PBS, and live cells were selected using a Ficoll gradient (Histopaque-1077, Sigma) (30 min at 400 RCF at RT, break 0). Cells were washed once in 5 mM EDTA/PBS and centrifuged (4 min at 500 RCF at RT) before proceeding with antibody labeling.

Tumor cells and blood cells were blocked in FACS buffer supplied with 20% normal goat serum (GIBCO) for 10 min on ice before labeling with the following antibodies: E-cad-eFluor660 (DECMA-1, eBioscience), biotin-conjugated anti-mouse CD41 clone eBioMWReg30 (eBioscience, cat. no. 13-0411-82) and anti-mouse CD45 clone 30-F11 (eBioscience, cat. no. 13-0451-85). Secondary labeling was performed using streptavidin-conjugated PerCP (Biolegend). Cells were sorted on a FACS Aria II Special Ordered Research Product (BD Biosciences). A broad FSC/SSC gate was followed by gates excluding doublets. Afterward, immune cells and megakaryocytes were excluded, based on staining for CD41 and CD45 in a dump channel. Tumor cells were subdivided as either RFP^+^ or GFP^+^ and further stringently gated for either absence of endogenous E-cad-mCFP expression and antibody staining (E-cad^LO^) or presence of high expression of E-cadherin and staining for Ab (E-cad^HI^ tumor cells). Data were manually analyzed with FlowJo.

### RNA isolation {#sec3.4.3}

RNA was isolated using Trizol reagent (Invitrogen Life Technologies) according to the manufacturer's protocol. The amount and purity of isolated RNA was analyzed by the Nanodrop spectrophotometer (Wilmington, DE, USA).

### cDNA preparation and qPCR {#sec3.4.4}

cDNA was prepared using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's protocol. Sequences of used primers can be found below. qPCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems). Thermal cycle conditions used for all qPCR reactions were as follows: 5 min at 95°C, followed by 40 cycles consisting of denaturation for 30 s at 95°C, annealing for 30 s at 60°C, and extension for 1 min at 72°C. PCR reactions were concluded with incubation for 10 min at 72°C to complete the extension of all synthesized products.

### Tail vein injection {#sec3.4.5}

FACS-sorted cells were resuspended in sterile PBS and injected in the tail vein of acceptor mice (100 μl per mouse). 3 months after injection acceptor mice were sacrificed and lungs were inspected for presence of metastases under a fluorescence-stereo microscope (Leica). Tissues were fixed using periodate-lysine-4% paraformaldehyde (PLP) buffer overnight at 4°C, incubated in 30% sucrose overnight at 4°C and embedded in Tissue Freezing medium (Leica Biosystems). Organs were cryo-sectioned (50 μm) and metastases were imaged with an inverted Leica TCS SP8 confocal microscope. All images were collected in 12 bit with 25X water immersion objective (HC FLUOTAR L N.A. 0.95 W VISIR 0.17 FWD 2.4 mm).

Quantification and Statistical Analysis {#sec3.5}
---------------------------------------

Data were analyzed using Prism v7 (GraphPad). Statistical significance for relation was assessed by linear regression. Data were normalized in some cases. And either single values per mouse or mean ± standard division are plotted throughout the manuscript.

Data and Code Availability {#sec3.6}
--------------------------

This study did not generate any unique datasets or code.
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